News

ChromaDex to Share Q3 2024 Results with Investors Soon

ChromaDex to Share Q3 2024 Results with Investors Soon

ChromaDex Corporation's Upcoming Financial Results

ChromaDex Corp. (NASDAQ: CDXC), a leader in nicotinamide adenine dinucleotide (NAD+) research focused on promoting healthy aging, is gearing up to report its financial results for the third quarter of 2024. The report is set to be released following the close of the market on Thursday, October 31, 2024. This announcement is part of the company’s commitment to transparency and engagement with its investors.

Conference Call Scheduled for Updates

In conjunction with the financial results, ChromaDex management has scheduled a conference call for Wednesday, November 6, 2024, at 4:30 p.m. ET. During this call, the leadership team will discuss the quarterly outcomes and provide insights into ongoing business developments. Participation is encouraged, and attendees are advised to join the call at least ten minutes early to ensure a smooth experience.

Important Details for Participants

Participants in the conference call can use the following information:
Date: Wednesday, November 6, 2024
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-596-4144
Conference ID: 8584242

Live Broadcast and Replay Options

The call will be broadcast live for public access, and those who cannot attend the live session will have the option to listen to the replay later. The replay of the conference call will be available from 7:30 p.m. EDT on November 6, 2024, to 11:59 p.m. EDT on Wednesday, November 13, 2024. The toll-free number for the replay is 1-800-770-2030, using Replay ID: 8584242#.

Company Overview: ChromaDex's Mission

ChromaDex Corp. (NASDAQ: CDXC) has established itself as a prominent authority in NAD+ research, a crucial component related to aging and overall wellness. The findings from their research arm have drawn attention for their contributions to understanding better ways to maintain vitality as people age. The company employs a team of renowned scientists who collaborate with prestigious universities and research institutions globally, exploring the potential of NAD+.

Niagen: The Innovative Ingredient

ChromaDex is known for its patented ingredient, Niagen, which is scientifically recognized as a superior NAD+ booster. This ingredient is available in its flagship product, Tru Niagen®, widely regarded as the leading NAD+ supplement in the United States. Niagen is essential for cellular functions and tends to decline with age, making it vital for enhancing overall well-being.

FDA Registered Products

The company ensures that Niagen® meets stringent quality and safety benchmarks by supplying pharmaceutical-grade formulations specifically for clinics that offer intravenous and injectable solutions. These products are intended for patients under medical supervision and are only available through prescription.

Advancements in Healthy Aging

As ChromaDex continues to innovate within the realm of healthy aging, their commitment to exploring the complexities of NAD+ remains a principal focus. Their extensive patent portfolio underlines their dedication to protecting their discoveries and developments in this field. For more information on the latest advancements, including research and product releases, the company regularly updates its stakeholder materials through its primary website.

Frequently Asked Questions

What are the financial results ChromaDex will report?

ChromaDex will detail its third quarter 2024 financial performance, alongside a business update in the upcoming conference call.

When will the earnings conference call occur?

The earnings conference call is scheduled for November 6, 2024, at 4:30 p.m. ET.

How can I attend the ChromaDex conference call?

Participants can join via the toll-free number provided and should log in at least ten minutes before the start.

Is there a replay available for the conference call?

Yes, the call will be available for replay from November 6, 2024, at 7:30 p.m. EDT until November 13, 2024.

What products does ChromaDex offer?

ChromaDex offers Niagen®, a clinically proven supplement for boosting NAD+ levels, among other nutraceuticals aimed at promoting healthy aging.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JLL Snaps Up Prime Boston Warehouse for $36M

Updated Category News Views 88

Diving Deep into JLL's Latest Acquisition If you blinked, you might have missed JLL Income Property Trust's latest power move. These folks just laid down $36 million for a prime 54,000-square-foot Class A distribution hub in Northborough, Massachusetts. This isn't just any run-of-the-mill facility; it's 100% leased to a heavy-hitting tenant for the next 14 years with neat...

Continue Reading
SlidesAI Launches Standalone Platform for Presentations

Updated Category News Views 95

From Add-on to Standalone: SlidesAI's Big Leap You know what they say: time waits for no one, and that seems true in tech too. Those suit-and-tie presentation days? SlidesAI just took a swing at redefining them. Once a trusty sidekick locked into Google Slides, it's now captaining its own ship. Welcome to the SlidesAI standalone presentation platform—where AI meets your...

Continue Reading
Tigo Energy Faces Legal Heat Over Fraud Allegations

Updated Category News Views 51

Tigo Energy's Legal Battle Heats Up If you haven't been paying attention, it’s time to get your eyes on Tigo Energy (NASDAQ: TYGO). The company is now in the hot seat with a securities fraud lawsuit that's got investors on edge. This isn’t just a minor squabble; we're talking about allegations that could shake the ground beneath its share price. The Claims and...

Continue Reading
How Octopus AI Reinvents Financial Processes in 2026

Updated Category News Views 102

Stepping into 2026, the buzz in enterprise finance isn’t about a new gadget or slick marketing trick; it's about complex financial processes being tamed by artificial intelligence. Octopus AI is trying to spearhead this transition by automating the intricacies of financial workflows while ensuring that human judgment remains at the helm. The Austin, Texas outfit laid...

Continue Reading
Africa-Caribbean Trade Potential: A $1.65B Opportunity

Updated Category News Views 29

Untapped Opportunities Between Africa and the Caribbean Who's ready to shake up the trade game between Africa and the Caribbean? According to a fresh-off-the-press report from the International Trade Centre (ITC) and Afreximbank, we could be looking at a whopping $1.65 billion in annual trade between these two regions by 2030. That's right, a billion with a 'B'. But let...

Continue Reading
Multiconsult's Q3 2026 Results: A Gradual Rebound

Updated Category News Views 50

Peering into the Q3 Crystal Ball When a company drops its quarterly results, it's like unveiling a new episode in an ongoing drama, and the Multiconsult ASA (Oslo: MULTI) saga is no exception. In their third quarter of 2026, the performance started to show signs of life following a somewhat sluggish run. While the numbers aren't sky-high, they're a solid indication that...

Continue Reading
BRIJ Medical Secures $5M: Paving Path for Product Launches

Updated Category News Views 14

In a world where medical advancements keep shifting gears, BRIJ Medical just pulled a fast one by closing a $5 million financing round—outpacing their original $3 million target. What drove this sudden increase? Well, it's simple. Their existing investors spotted an opportunity too ripe to pass up, proving yet again, money talks when confidence backs it up. Expanding...

Continue Reading
Memoir 'Pinball' Explores Life's Unpredictable Momentum

Updated Category News Views 91

Funny how some folks think life has a road map. Let me tell you, it's more like a pinball machine, barely controllable and ready to surprise you with a tilt at any moment. And that's the essence of Marshall Barber's new memoir, 'PINBALL: Remembrances of a Flaneur.' Life's Roulette: Choices and Chance Barber takes readers on a raw ride through the byways of a life...

Continue Reading
ALS Research Gains Momentum as ACT for ALS Law Signed

Updated Category News Views 58

A Major Stride in ALS Advocacy Today's not your usual day at the office for the folks championing the fight against ALS. With the President putting pen to paper, the ACT for ALS Act just turned into law, sending ripples through the community. Let me tell ya, legislation like this doesn't float by on a cloud—it's the result of grit, sleepless nights, and a dash of...

Continue Reading
OSL Unveils Instant Redemption for USDGO Plus SP

Updated Category News Views 98

OSL's New Move: Instant Redemption on the Table Alright, let's chew over OSL's latest gambit—you know, those folks (HKEX: 863) who are knee-deep in the digital currency swamp. They've launched this "Instant Redemption" feature for these fancy real-world asset products, and USDGO Plus SP is right there at the forefront. Getting the Fine Print Straight Now, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

FIS Enhances Instant Payment Solutions with FedNow Certification

Updated Category News Views 366

FIS Enhances Instant Payment Solutions with FedNow Certification FIS (NYSE: FIS), a prominent player in the financial technology sector, has recently announced a significant advancement in its services by obtaining certification for send capabilities within the Federal Reserve’s FedNow instant payment service. As one of the early adopters in fintech to achieve this...

Continue Reading
Emergent BioSolutions Takes Important Steps Against Opioid Crisis

Updated Category News Views 163

Emergent BioSolutions Takes Critical Steps Against Opioid Crisis In an effort to combat the escalating opioid poisoning epidemic, Emergent BioSolutions Inc. (NYSE: EBS) has renewed its commitment to fighting this public health crisis through a multi-faceted approach. This includes promoting awareness, education, and ensuring wide access to life-saving naloxone treatments,...

Continue Reading
HealthEquity Shares Exciting Projections for HSA Growth

Updated Category News Views 151

HealthEquity's Record Year-End HSA Sales Expectations HealthEquity, Inc. (NASDAQ: HQY), recognized as the leading health savings account (HSA) custodian in the nation, has reported exceptional estimates for HSAs, HSA assets, and total accounts for its fiscal year ending January 31, 2025. These estimates showcase a remarkable sales year, demonstrating significant growth in...

Continue Reading
Innovative Changes at Hydromer to Transform Product Development

Updated Category News Views 95

Hydromer, Inc. Restructures for a New Era of Innovation Hydromer, Inc. (OTC: HYDI) has made an exciting announcement regarding significant changes aimed at boosting its research and development capabilities. This restructuring comes after over 44 years of providing innovative hydrophilic coating solutions for both medical and industrial applications. The company is...

Continue Reading
Insights into Archer Aviation's Market Position

Updated Category News Views 170

Archer Aviation's Current Market Standing Archer Aviation Inc (NYSE: ACHR) has recently seen a notable decline in short interest, now standing at 17.05% of its float. This statistic reflects a decrease of 3.12% from previous reports, indicating a shift in investor sentiment. Currently, there are approximately 92.77 million shares of Archer Aviation sold short....

Continue Reading